OB-Tools

Company Overview

Snapshot

Founded in January 2003, OB-Tools operates with 11–50 employees, developing medical devices for maternal and fetal monitoring. A key milestone for the company was receiving FDA approval for its fetal heart rate monitoring unit in 2015.

Business overview

OB-Tools develops technology for noninvasive uterine and fetal monitoring, primarily focusing on maternal fetal medicine specialists and obstetricians. Its core product, the TrueLabor System with LaborTrack Technology, is a device designed to identify, measure, and evaluate uterine contractions and fetal heart rates throughout pregnancy and labor. The company serves the healthcare industry, operating within the Health Tech & Life Sciences sector, specifically in medical devices and digital healthcare for patient remote monitoring.

Strategic signal

In September 2015, OB-Tools announced its intention to begin marketing its non-invasive labor monitoring device following its FDA approval. This event signaled a critical transition from development to commercialization, indicating market readiness and regulatory validation for its TrueLabor System. For investors, this marked a significant de-risking event and a clear path to market entry within the medical device sector.

Company Intelligence Q&A

What is the primary focus of OB-Tools?

OB-Tools develops noninvasive technology for monitoring uterine contractions and fetal heart rates throughout pregnancy and labor, primarily for maternal fetal medicine specialists and obstetricians.

What is the TrueLabor System?

The TrueLabor System with LaborTrack Technology is OB-Tools' noninvasive device designed to help medical professionals identify, measure, and evaluate uterine contractions and fetal heart rates.

When did OB-Tools receive FDA approval for its fetal heart rate monitoring unit?

OB-Tools' fetal heart rate monitoring unit received FDA approval in 2015.

What markets does OB-Tools target?

OB-Tools targets global markets, with a specific focus on the United States and Europe, for its medical monitoring devices.

What was a significant development for OB-Tools in September 2015?

In September 2015, OB-Tools announced it would begin marketing its non-invasive labor monitoring device after receiving FDA approval, indicating its readiness for commercialization.